

Dy




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : A61K 47/00, 37/02		A1	(11) International Publication Number: WO 89/12464
		(43) International Publication Date: 28 December 1989 (28.12.89)	
(21) International Application Number: PCT/US89/02575		(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).	
(22) International Filing Date: 13 June 1989 (13.06.89)			
(30) Priority data: 206,520 14 June 1988 (14.06.88) US		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).			
(72) Inventors: EDELMAN, Elazer, R. ; 45 Longwood Avenue, Apt. 308, Brooklin, MA 02146 (US). LANGER, Robert, S. ; 46 Greenville Street, Somerville, MA 02143 (US). KLAGSBURN, Michael ; 20 Calvin Road, Newton, MA 02160 (US). MATHIOWITZ, Edith ; 42 Alton Place, Brookline, MA 02146 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: CONTROLLED RELEASE SYSTEMS CONTAINING HEPARIN AND GROWTH FACTORS



(57) Abstract

A system for stabilizing fibroblast-derived growth factors, maintaining their bioactivity over a prolonged period of time and controllably releasing them for use is disclosed. The system uses growth factors bound to biocompatible substrates via heparin or heparin derived compounds to maintain the bioactivity of the growth factors. A growth factor bound to a heparin coated substrate can be used independently as a controlled release device, or can be incorporated into a reservoir or matrix type controlled release device to further enhance the controlled release properties. The stabilized growth factors can be implanted into a patient, thereby providing a means for producing an *in vivo* controlled release of a growth factor to the patient.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

-1-

CONTROLLED RELEASE SYSTEMS CONTAINING HEPARIN
AND GROWTH FACTORS

Description

Background of the Invention

5 It has become apparent that blood-borne and
blood vessel bound factors play a major role in the
propagation and persistence of a large number of
diseases in many different fields of medicine. The
growth of tumors, progression of arthritis, and
10 propagation of atherosclerosis are but a few of the
important clinical scenarios in which growth factor
(GF) control has been demonstrated.

 This control is presumed to stem from the basic
dependence of these diseases, and others like them,
15 on blood vessels for nourishment and support. The
growth and replication of the endothelial cells that
line the blood vessels and the smooth muscle cells
that surround the blood vessels appears to be
modulated by an expanding family of GFs. The growth
20 factors that stimulate endothelial cells have a
strong affinity for heparin. As such, the effects
of heparin and heparin avid growth factors and their
inhibitors are the subject of extensive study.

-2-

While heparin avid growth factors are highly potent, they tend to degrade rapidly and are currently in short supply. Thus, they cannot be ingested or injected and in vivo studies, if possible at all, are limited to only the most short term effects of minute quantities of factor.

The technology of controlled drug delivery provides an effective means of storing and delivering a wide variety of pharmaceuticals. Unfortunately, the development of a controlled release growth factor system has been hindered by a number of significant problems. Key among these are denaturation and loss of biological activity when such factors are stored for prolonged periods, as well as enhanced loss when exposed to the procedures of standard controlled release device (CRD) fabrication. For example, even if stored in the most concentrated formulations at optimum temperatures, over 90% of the biological activity of many growth factors is lost in four weeks.

In addition, conventional means of CRD encapsulation press or dissolve an encapsulating material around the pharmaceutical. This generally requires exposing a mixture of the pharmaceutical and the encapsulating material to an elevated temperature, pressure or ionic strength. Extremes of pH or contact with organic solvents might also be required. Each of these exposures is known to drastically denature growth factors.

Additionally, simply encapsulating microliter quantities of growth factors has proven problematic.

-3-

It is exceedingly difficult to obtain uniform dispersion of such a small quantity of liquid within any of the conventional controlled release devices. Attempts to overcome this drawback by dilution with
5 other liquids or lyophilization of the growth factors in combination with other powdered materials have enhanced the loss of biological activity.

Thus, a need exists for a method for preventing the denaturation and loss of bioactivity of growth
10 factors when stored for prolonged periods. Additionally, a need exists for a controlled release device compatible with growth factors that would allow them to be released at a generally uniform, or at least predictable, rate over a period of time.

15 Summary of the Invention

This invention pertains to a device for stabilizing heparin bound growth factors and controlling their release rate. More specifically, this invention pertains to a device wherein growth
20 factors which bind to heparin and heparin-derived substances are stabilized by forming a complex between a growth factor and heparin or heparin-derived substances and binding the complex to a biocompatible substrate. The biological activity of
25 growth factors contained in this heparin/growth factor complex has been found to be significantly maintained over prolonged time periods, especially when compared to unbound growth factor samples.

The stabilized growth factors of this invention
30 exhibit a controlled release from heparin-bound

-4-

substrate surfaces. This controlled release can be further enhanced by incorporating the growth factor/heparin/substrate unit into a conventional controlled release device. Satisfactory results
5 have been demonstrated using the two basic types of CRDs, reservoir-type and matrix-type controlled release devices. Both types of controlled release devices are suitable for implantation and in vivo release of growth factors.

10 The advantages of this invention include the ability to store growth factors for prolonged periods while maintaining a significant amount of biological activity, and the ability to incorporate growth factors into devices for controllable release
15 over extended periods without destroying biological activity. The devices of this invention are simple to produce, easy to store and use, and inexpensive when compared to the cost of the growth factor itself.

20 Brief Description of the Drawings

Figure 1 is a plot of the release rate and bioactivity over time for fibroblast-derived growth factor (FGF) bound to heparin-coated dextran beads.

Figure 2 is a plot of the release rate and
25 bioactivity over time for a heparin-bound FGF suspended in a sodium alginate capsule.

Detailed Description of the Invention

The methods described herein have been found to
30 work successfully with fibroblast derived growth factor (FGF) because of its heparin affinity.

-5-

Fibroblast derived growth factors (both acidic and basic) are 154-amino acid polypeptides blocked at the amino terminus. They are believed to play a major role in angiogenesis, response to injury and tissue repair. A more detailed discussion of various FGFs and related growth factors is presented by Folkman and Klagsbrun in Science, 235, 442 (1987), the teachings of which are incorporated herein by reference. Unfortunately, as stated previously, FGF tends to denature and lose activity when stored for prolonged periods of time, especially at elevated temperatures.

Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans, of molecular weights that average 15,000 daltons. Commercial heparin comprises polymers of two repeating disaccharide units: D-glucosamine-L-iduronic acid and D-glucosamine-D-glucuronic acid. Heparin is strongly acidic because it has a high content of covalently linked sulfate and carboxylic acid groups.

Related to heparin, and therefore also useful with this invention are substances such as heparan sulfate. As used herein, however, unless specifically distinguished, the term heparin is intended to apply to both heparin and heparin-derived compounds such as heparan sulfate.

Heparin and heparin-derived compounds have been found to stabilize many of the storage losses of FGF, especially those resulting from elevated temperatures. Furthermore, the stabilizing effect

-6-

of heparin and derived substances has been combined with its ability to bind FGF. This binding ability allows the formation of a stable growth factor carrier in a solid form.

5 More specifically, heparin can bind to the surfaces of a wide variety of materials by enzymatic linking. Thus, growth factors that can bind to heparin, such as the FGFs, can then be made to stick to the surface of these materials, thereby allowing
10 the use of a variety of sustained release devices using growth factors.

 A variety of controlled release devices can be produced which utilize the induced stability of growth factors when bound to heparin. The two basic
15 CRDs are reservoir and matrix systems. In a reservoir CRD, the material to be released is housed within a porous envelope. The envelope surrounds a central core or reservoir of solid, liquid or gas which contains the material to be released. The
20 core material must be able to diffuse through the envelope material and the rate of release depends upon the rate of diffusion as well as the porosity and tortuosity of pores within the envelope. Large molecular compounds, therefore, are poorly and
25 erratically released from these systems.

 Controlled release of large molecular compounds can be achieved by using a matrix type CRD. In this system, the substance to be released is incorporated within the wall of the device. The word "matrix"
30 refers to the homogeneous dispersion of drug through the wall of supporting material. The substance to

-7-

be released is mixed as a dry powder with the supporting material. The mixture is then fabricated into a single monolithic device. The powder creates "caves" or channels within the device whose supporting walls are made up of the second material. If the molecular weight of the substance is large enough, it will not diffuse through the walls; rather, it must pass through the tortuous network of connecting channels to be released. The rate of release is dependent upon the ability of the environmental fluid to enter the matrix, solubilize the substance or drug, and leach the solubilized substance out of the matrix. The leaching time is determined not only by the net diffusivities of the substance and its solvent, but also by the porosity, tortuosity and hydrophilicity of the matrix and the size and concentration of the substance embedded within the device.

Both reservoir-type and matrix-type CRDs can be produced from biocompatible materials. Use of such materials allows the device to be implanted into a patient, thereby providing an in vivo controlled release of growth factor to the patient.

Regardless of whether a reservoir or matrix CRD is to be used, it is first necessary to provide a heparin/growth factor complex bound to an immobilizing substrate. One suitable variety of substrates is the family of crosslinked dextran beads. As used herein, the term beads refers to small, discrete particles upon which a substance can be bound. Often, although not always, the beads

-8-

useful in this invention are porous and are formed from polymers. A preferred bead substrate comprises diethylaminoethyl (DEAE)-substituted dextran beads. These beads are commercially produced by Pharmacia
5 Fine Chemicals, Inc., Piscataway, NJ, under the tradename DEAE-Sephadex A50, an ion exchange system. Chemically, these beads are formed from a cross-linked dextran matrix having diethylaminoethyl groups covalently bound to the dextran chain. As
10 commercially available, DEAE-Sephadex A50 beads are believed to have a particle size of 40-120 um and a positive charge capacity of about 5.4 meq per gram of dry, crosslinked dextran (ignores weight of attached DEAE moieties). Other anion exchange
15 resins, such as DEAE-Sephadex A25, QAE-Sephadex A50 and QAE-Sephadex A25 are suitable. Uncharged crosslinked dextran beads sold by Pharmacia under various Sephadex and Sepharose tradenames are also suitable for use with this invention.

20 In a preferred embodiment of the invention, the growth factor is bound to heparin after the heparin is bound to a substrate such as the previously described dextran beads. Crosslinked dextran beads having bound heparin are available commercially, or
25 alternatively, can be produced by using cyanogen bromide to activate the surface of the beads, thereby allowing the surface to accept heparin. If growth factor is then passed over the beads, it sticks to the heparin which is bound to the bead
30 surface. Tests using radiolabelled growth factor have demonstrated that over 80% of the growth factor

-9-

passed over heparin-coated beads becomes bound to heparin.

Heparin-bound growth factor leaches off the beads at a steady and sustained rate. If desired, however, the growth factor can be almost entirely stripped from the beads by exposing them to high salt concentrations such as 3.0 M NaCl.

The rate of growth factor released from the heparin-coated beads has been studied both radioactively and bioactively. The radioactive data relates to the physical presence of growth factor, while the bioactive data relates to the biological activity of the material which is being released. A composite graph of both radioactive data and bioactive data is presented in Figure 1.

Figure 1 represents the rate of FGF release from heparin-sepharose beads. The radioactive data was compiled using FGF radiolabelled with iodine-125, (^{125}I), designated in the Figure as I*125. The bioactive data was compiled using a 3T3 assay and is designated in the Figure as 3T3. The 3T3 assay is described in detail by Sullivan and Klagsburn in J. Tissue Culture Meth., 10(2), 125 (1986), the teachings of which are incorporated herein by reference. Figure 1 shows that the rate of FGF release from the bead surface is about 5-7% per day which corresponds to a release rate of approximately 2 units per day for this dose formulation. About 25% of the physically detected growth factor was found to have remained biologically active.

-10-

The above data confirms that growth factor can be bound to heparin coated dextran beads and be used in the fabrication of controlled release devices. The growth factor which might otherwise lose most of its activity with handling or encapsulation can be easily transported and enveloped after binding with heparin. The continuous, slow leaching of growth factor from the beads constantly replenishes the source of growth factor to be released from a CRD.

These beads can be encapsulated within a controlled release device which stores the factor in the most biologically conservative form and provides for efficient encapsulation as well as an enhanced controlled release characteristic.

Many different methods, such as hot melt or solvent casting, for example, can be used to encapsulate heparin-bound growth factors. As a preferred embodiment of a reservoir system, however, heparin-bound growth factor is encapsulated in microspheres of sodium alginate. In this method, a sodium alginate solution is mixed with a measured quantity of heparin-dextran beads containing bound growth factor. This suspension is dropped into a hardening solution of calcium chloride. Spheres are formed as drops of the suspension enter the hardening solution. The ultimate size of the microspheres can be controlled by controlling the diameter of the orifice through which suspension droplets are formed. The porosity of the sodium alginate envelope is determined by the degree of crosslinking of the alginate. The degree of crosslinking is

-11-

dependent upon the residence time of the spheres in the calcium chloride bath. The greater the residence time, the harder the sodium alginate wall becomes.

5 Figure 2 is a release profile of FGF from sodium alginate capsules for capsules allowed to harden for five minutes. As in Figure 1, radio-labelled growth factor was used, and physical release was contrasted with biological activity. As
10 demonstrated in Figure 2, a slow, steady stream of growth factor was released through the wall of the device at approximately 1 unit per day.

 The stream depicted in Figure 2 represents growth factor which has leached off the heparin-dextran beads and diffused through the calcium-hardened, sodium alginate envelope. Figure 2 also
15 represents the bioactivity of the released FGF, showing that about 85% of the factor detected by ^{125}I gamma counting can be detected by the 3T3 cell synthesis assay.
20

 In contrast to FGF release profiles detected from similar beads not encapsulated, the bulk of what was released was released biologically intact. A number of possible explanations for this exist
25 including the polymerization of inactivated forms within the microcapsule such that they are not released, and the retention of biological activity in the protected environment of the microcapsule.

 The heparin-dextran beads containing bound
30 growth factor can also be incorporated into a matrix-type CRD. While numerous methods for forming

-12-

matrix CRDs are available, few are suitable for use with growth factors. In the preferred embodiment, FGF laden heparin-dextran beads are incorporated within the matrix using compression molding. In
5 this method, a biologically inert polymeric material, such as the preferred ethylene-vinyl acetate copolymer (EVAc) is ground into fine particles. The substance to be embedded, in this case the growth factor laden beads, is mixed with the particulate
10 polymeric material. This mixture is then placed in a compression chamber and compressed on a high pressure press to cause the two substances to meld together into a single structure. This device can then be implanted into a patient to provide a
15 sustained release of the growth factor.

The beads of this invention have been mixed with EVAc and compressed. The resulting fabricated device had a generally supporting network of EVAc with interconnecting channels which housed the
20 growth factor laden heparin-dextran beads.

Although the devices described in detail herein have been sodium alginate capsules and EVAc matrices, the invention is not intended to be limited to these embodiments. Any number of non-
25 erodable, synthetic biocompatible materials can be used in the devices described herein. Additionally, bioerodable polymers such as polyanhydrides, polylactic acids, polyglycolic acids and copolymers thereof can be used in the practice of this inven-
30 tion.

-13-

Crosslinked dextran beads have been used as a substrate for the devices described herein, however, practically any biocompatible surface can be used as a substrate for heparin. Furthermore, a bead
5 geometry was chosen for its large surface area; however, the substrate can be of any size or shape suitable for in vivo use.

Equivalents

Those skilled in the art will recognize, or be
10 able to ascertain applying no more than routine experimentation, many equivalents to the specific embodiments described above. Such equivalents are intended to be encompassed within the following claims.

-14-

CLAIMS

1. A device for controlling the release rate of a fibroblast derived growth factor which comprises a substrate having heparin or a
5 heparin derived compound bound thereto and the growth factor bound to the heparin or heparin derived compound.
2. A device as in Claim 1 wherein the substrate comprises beads.
- 10 3. A device as in Claim 2 wherein the beads comprise crosslinked dextran beads.
4. A device as in Claim 1 wherein said device further comprises an encapsulation means.
- 15 5. A device as in Claim 4 wherein the encapsulation means comprises a sodium alginate envelope.
6. A device as in Claim 1 wherein said device is contained within a polymeric matrix.
- 20 7. A device as in Claim 6 wherein the matrix comprises ethylene-vinyl acetate copolymer.
8. A device as in Claim 6 wherein said device system is contained within a bioerodable polymer.

-15-

9. A device system as in Claim 8 wherein the bioerodable polymer is selected from the group consisting of polyanhydrides, polylactic acids, polyglycolic acids and copolymers thereof.
- 5 10. A method for producing a device for the controlled release of fibroblast derived growth factors comprising the steps of:
- 10 a. providing a substrate having heparin or a heparin-derived compound bound to the substrate surface; and
- b. contacting the substrate with the growth factor for a time sufficient to allow the growth factor to bind to the heparin or the heparin-derived compound.
- 15 11. A method as in Claim 10 wherein the substrate comprises beads.
12. A method as in Claim 11 wherein the beads comprise crosslinked dextran beads.
- 20 13. A method as in Claim 12 wherein the heparin or heparin-derived compound is bound to the beads by a method comprising the steps of:
- a. contacting the beads with cyanogen bromide under conditions which activate the bead surface; and
- 25 b. contacting the activated bead surface with the heparin or heparin-derived compound under conditions which allow the heparin

-16-

or heparin-derived compound to bind to substantially all of the bead surface so contacted.

- 5 14. A method as in Claim 9 further comprising the step of encapsulating the growth-factor-bound substrate within a reservoir.
- 15 15. A method as in Claim 14 wherein the growth-factor-bound substrate is encapsulated within a material comprising sodium alginate.
- 10 16. A method as in Claim 15 wherein the encapsulation step comprises the steps of:
 - a. mixing the growth-factor-bound substrate with a solution comprising sodium alginate to form a suspension;
 - 15 b. contacting droplets of the suspension with a hardening solution to form spherical envelopes containing the suspension; and
 - c. allowing the spherical envelopes to remain in the hardening solution until they have
 - 20 hardened to a desired degree.
17. A method as in Claim 16 wherein the hardening solution comprises calcium chloride.
18. A method as in Claim 10 further comprising the steps of encapsulating the growth-factor-bound
25 substrate within a polymeric matrix.

-17-

19. A method as in Claim 18 wherein the polymeric matrix comprises ethylene-vinyl acetate copolymer.
20. A method as in Claim 18 wherein the encapsulation step comprises the steps of:
- a. providing a particulate polymer;
 - b. mixing the growth-factor-bound substrate with the particulate polymer to provide a substrate/polymer mixture;
 - 10 c. compressing the substrate/polymer mixture under conditions which allow the growth-factor-bound substrate and the polymer to become melded into a single structure.
21. A method as in Claim 18 wherein the polymeric material is bioerodable.
22. A method as in Claim 21 wherein the bioerodable polymeric material is selected from the group consisting of polyanhydrides, polylactic acids, polyglycolic acids and copolymers thereof.
- 20 23. A reservoir-type sustained release device for the sustained release of fibroblast-derived growth factors which comprises:
- a. a biocompatible substrate having heparin or a heparin-derived compound bound thereto and the growth factor bound to the heparin or heparin-derived compound;
 - 25

-18-

- b. a sodium alginate solution surrounding the growth-factor-bound substrate; and
 - c. a hardened sodium alginate envelope surrounding the solution and growth-factor-bound substrate.
- 5
24. A matrix-type sustained release device for the sustained release of fibroblast-derived growth factors which comprises:
- a. a biocompatible substrate having heparin or a heparin-derived compound bound thereto and the growth-factor-bound to the heparin or heparin-derived compound; and
 - b. a polymeric matrix acting as a supporting framework having a plurality of inter-connecting channels which house the growth-factor-bound substrate.
- 10
- 15




Figure 1

4/2




Figure 2

INTERNATIONAL SEARCH REPORT

PCT/US 89/02575

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 47/00, A 61 K 37/02		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	Molecular Endocrinology, vol. 2, no. 7, 1988, Endocrine Soc. (US) P.R. Murphy et al.: "Fibroblast growth factor messenger ribonucleic acid expression in a human astrocytoma cell line: regulation by serum and cell density", pages 591-598, see page 591, left-hand column, lines 1-7; page 591, right-hand column: "introduction" --	1-4,10-13
Y	Chemical Abstracts, vol. 105, no. 1, 1989, (Columbus, Ohio, US), P. Walicke et al.: "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension" see abstract 13102 & Proc. Natl. Acad. Sci. USA 83(9), 3012-3016 --	1-4,10-13
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
9th October 1989	14. 11. 89	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	T.K. WILLIS	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	EP, A, 0086186 (O. LARM) 17 August 1983, see page 1, lines 8-22; page 6, lines 22-28; examples 6,10; claims 6,7,8,11,12 --	1-4,10-13
P,Y	Journal of Chromatography, vol. 476, 1989, Elsevier Science Publishers BV (Amsterdam, NL) F.L. Zhou et al.: "Coated silica supports for high-performance affinity chromatography of proteins", pages 195-203, see page 195, summary, introduction; page 196, paragraphs 4,5 --	1-4,10-13
A	Experimental Neurology, vol. 102, 1988, Academic Press, Inc. P.A. Walicke: "Interactions between basic fibroblast growth factor (FGF) and glycosaminoglycans in promoting neurite outgrowth", pages 144-148, see page 144, left-hand column, abstract -----	1-24

US 8902575
SA 29462

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

EPC FORM 1047

THIS PAGE BLANK (USPTO)